Company intelligence / Profile preview

NuSirt Biopharma

Nashville, Tennessee, United Statesnusirt.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

NuSirt’s clinical studies have shown that its patented combinations can improve outcomes in chronic metabolic diseases. The lead program has completed a Phase 2A trial for type 2 diabetes, while another program targeting NAFLD/NASH is at the Phase II stage. Preclinical data suggest potential to reverse NAFLD, reduce symptoms, and prevent NASH onset. The approach may also lower required doses of established drugs, potentially improving patient compliance.

Therapeutic areas: GastroenterologyEndocrinology
Modalities: Small moleculesAmino acid combinations (notably leucine with existing drugs)
Industry: Biotech

Drug pipeline

1 asset

NuShape

Unknown

Beyond the preview

Go deeper on NuSirt Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NuSirt Biopharma.

Explore the full profile